More on ARCT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.07 |
|
|||
| Open | $10.84 | ||||
| 52 Wk High | $13.09 | ||||
| 52 Wk Low | $5.54 | ||||
| Day High | $11.33 | ||||
| Day Low | $10.42 | ||||
| P/E | N/A | ||||
| EPS | $-0.38 | ||||
| Volume | 358,762 | ||||
- Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC.
- Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald
- Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG
- Citi Upgrades Arcturus Therapeutics (ARCT) to Buy
- Form 8-K Arcturus Therapeutics For: Sep 23
- Arcturus shares Phase 2 OTC data, unveils new mRNA platform
- Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
- Arcturus Therapeutics to present Phase 2 OTC deficiency data
- Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
- Form 8-K Arcturus Therapeutics For: Aug 25
Entities mentioned with ARCT
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
